Summit Therapeutics-Spon ADRSMMT
13F holders, Q1 2025 (March 31)10holders +3
5new positions
2sold out
$19.15avg. 13F price*
At the end of Q1 2025, 10 institutions reported holding Summit Therapeutics-Spon ADR (SMMT) in their 13F filings, up 3 from Q4 2024. 5 opened new positions and 2 sold out. The largest holders were Lindbrook Capital, LLC ($16K), Farther Finance Advisors, LLC ($12K) and EverSource Wealth Advisors, LLC ($9K).
- Company
- Summit Therapeutics-Spon ADR
- CUSIP
- 86627R102
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $3K |
| Exits | 2 | $180K |
All 13F filers, Q4 2024 → Q1 2025: 1,014 shares bought and 10,112 shares sold, net −9,098 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Lindbrook Capital, LLC | 0.00% | Add +11.7% | 843 | $16K |
| Farther Finance Advisors, LLC | 0.00% | Add +5350.0% | 654 | $12K |
| EverSource Wealth Advisors, LLC | 0.00% | Add +8.4% | 453 | $9K |
| Rothschild Investment LLC | 0.00% | Add +62.5% | 195 | $4K |
| Guardian Wealth Management, Inc. | 0.00% | New | 70 | $1K |
| Rise Advisors, LLC | 0.00% | New | 55 | $1K |
| AdvisorNet Financial, Inc | 0.00% | New | 22 | $424 |
| Parallel Advisors, LLC | 0.00% | New | 19 | $367 |
| Global Financial Private Client, LLC | 0.00% | Add +400.0% | 5 | $96 |
| Bay Harbor Wealth Management, LLC | 0.00% | New | 4 | $77 |
"% of holder's portfolio" is SMMT's weight in each manager's 13F, not the share of Summit Therapeutics-Spon ADR the manager owns.